Quantum BioPharma Ltd.

NasdaqCM:QNTM Stock Report

Market Cap: US$24.4m

Quantum BioPharma Balance Sheet Health

Financial Health criteria checks 0/6

Quantum BioPharma has a total shareholder equity of $-1.4M and total debt of $786.1K, which brings its debt-to-equity ratio to -55.4%. Its total assets and total liabilities are $14.9M and $16.3M respectively.

Key information

-55.36%

Debt to equity ratio

US$786.07k

Debt

Interest coverage ration/a
CashUS$4.56m
Equity-US$1.42m
Total liabilitiesUS$16.35m
Total assetsUS$14.93m

Recent financial health updates

Recent updates

Seeking Alpha • Sep 29

FSD Pharma receives Nasdaq minimum bid price deficiency notification

FSD Pharma (NASDAQ:HUGE) received Nasdaq notification stating the company is not in compliance with the minimum bid price requirement.  The company’s class B subordinate voting shares has not maintained a minimum bid price of $1.00/share for the 30 consecutive business days from August 15, 2022 to September 26, 2022. The company has been provided 180 calendar days, or until March 27, 2023, to regain compliance. If the company does not regain compliance by March 27, 2023, the company may be eligible for additional time to regain compliance or may face delisting from Nasdaq.
Seeking Alpha • Sep 06

FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada

FSD Pharma (NASDAQ:HUGE) received clearance from the U.S. Food and Drug Administration (FDA) and Health Canada to start a phase 2 trial of FSD201 to treat nociplastic pain associated with idiopathic mast cell activation (IMCA) syndrome. Mast cell activation syndrome causes mast cells to release an abnormal amount of chemicals into the body, which causes allergy symptoms and other symptoms. The company noted that FSD201 has shown to be safe and well tolerated in a phase 1 trial. "We are working with our clinical sites in the U.S. and Canada to initiate the study and intend to release more details on the study very soon, said Lakshmi Kotra, CEO of FSD Pharma unit Lucid Psycheceuticals.

Financial Position Analysis

Short Term Liabilities: QNTM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: QNTM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: QNTM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: QNTM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QNTM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: QNTM has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.4% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/20 08:33
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quantum BioPharma Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Karen SterlingKingswood Capital